checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA delivers rapid and sustained relief from pruritus1*

OTEZLA significantly reduces pruritus severity as early as week 21

 

SUSTAINED REDUCTIONS IN PRURITUS UP TO 32 WEEKS1,a

otezla efficacy on pruritis
a

ESTEEM® 1 study. Data as observed from patients in the full analysis set. Results were consistent between ESTEEM 1 and ESTEEM 2.

  • Among patients treated with OTEZLA 30 mg BID, improvements in pruritus VAS scores correlated with DLQI scores (rs = 0.55 [week 16]; rs ≥ 0.51 [week 32]; P < 0.001)1
*

Pruritus was measured on a 100-mm VAS. Baseline values: Placebo, 65.0 mm; OTEZLA 30 mg BID, 66.1 mm.

BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.

Reference: 1. Sobell JM, Foley P, Toth D, et al. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. Acta Derm Venereol. 2016;96(4):514-20.


Select an e-mail client to share

close x